CHICAGO–(BUSINESS WIRE)–The board of directors of Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today declared a quarterly dividend of 50 cents per share, consistent with the dividend paid in July. The dividend is payable Oct. 30, 2026, to shareholders of record as of Oct. 2, 2026. Please contact investors@morningstar.com with any questions. About Morningstar, Inc. Morningstar, Inc. is a leading provider of independent investment insights in North Am

WEST PALM BEACH, Fla.–(BUSINESS WIRE)–RiverNorth Opportunities Fund, Inc. (NYSE: RIV) (the “Fund”) has closed a $75 million private offering of Series B Mandatory Redeemable Preferred Shares, due September 18, 2031 (the “MRPS”). The MRPS are rated A1 by Moody’s Ratings. Net proceeds from the offering of the MRPS will be used primarily to refinance the Fund’s existing debt and to make new portfolio investments. The table below sets forth the key terms of the MRPS issued.   Series Amount ($ MM)

JERSEY CITY, N.J.–(BUSINESS WIRE)–Copper Property CTL Pass Through Trust (“the Trust”) has filed a Form 8-K containing the Q2-2026 consolidated financial statements of Penney Intermediate Holdings LLC for the three months ended August 1, 2026 and August 2, 2025, respectively, and related Master Lease store performance disclosures. Additional information, including the Trust’s Monthly and Quarterly Reports, as well as other filings with the Securities and Exchange Commission (“SEC”) can be acc

AUSTIN, Texas–(BUSINESS WIRE)–IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved AQNEURSA® (levacetylleucine) for the treatment of ataxia in adult and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. AQNEURSA is the first and only drug approved for the treatment of A-T anywhere in the world. In the United

NEW YORK–(BUSINESS WIRE)–MVLAND, la plateforme de création de clips musicaux par IA développée par Meitu, passe à la version 2.0 et lance officiellement son Studio Mode. Articulée autour d’un workflow créatif piloté par des agents IA et d’une analyse musicale professionnelle, cette mise à jour intègre l’ensemble du processus de production d’un clip musical — de la compréhension de la musique et du développement créatif au storyboard, à la génération des plans et au montage de postproduction —

NEW YORK–(BUSINESS WIRE)–MVLAND, a Meitu-developed AI music video generator, has upgraded to Version 2.0 and officially launched its Studio Mode. Centered on an agent-driven creative workflow and professional music analysis, the update integrates the entire MV production pipeline — from music understanding and creative development to storyboarding, shot generation and post-editing — into one unified end-to-end workflow. Unlike conventional prompt-based AI tools that only generate fragmented c

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), een bedrijf in de commerciële fase dat zich bezighoudt met het onderzoek naar en de ontwikkeling van geneesmiddelen voor de behandeling van ernstige endocrinologische, oncologische, metabole en neurologische aandoeningen door de werking van het hormoon cortisol te beïnvloeden, heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau h

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), un’azienda di fase commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie endocrine, oncologiche, metaboliche e neurologiche attraverso la modulazione degli effetti dell’ormone cortisolo, oggi ha annunciato che il Comitato per i Medicinali per Uso Umano (CHMP) dell’Agenzia europea per i medicinali (EMA) ha raccomandato l’approvazione da parte della Commissione

REDWOOD CITY, California–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), una empresa de fase comercial dedicada al descubrimiento y el desarrollo de medicamentos para el tratamiento de trastornos endocrinológicos, oncológicos, metabólicos y neurológicos graves mediante la modulación de los efectos de la hormona cortisol, anunció hoy que el Comité de Medicamentos de Uso Humano (CMUH) de la Agencia Europea de Medicamentos recomendó que la Comisión Europea apruebe relacorilant,

REDWOOD CITY, Kalif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT) ist ein Unternehmen in der kommerziellen Phase, das sich mit der Erforschung und Entwicklung von Medikamenten zur Behandlung schwerer endokrinologischer, onkologischer, metabolischer und neurologischer Erkrankungen durch Modulation der Wirkung des Hormons Cortisol befasst. Es gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur der Europäischen Kommission (E

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.